CoChat

International regulatory landscape and integration of corrective genome editing into in vitro fertilization

Open access
Araki, Motoko, Ishii, Tetsuya · 2014 · Reproductive Biology and Endocrinology

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.

Abstract

Genome editing technology, including zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR)/Cas, has enabled far more efficient genetic engineering even in non-human primates. This biotechnology is more likely to develop into medicine for preventing a genetic disease if corrective genome editing is integrated into assisted reproductive technology, represented by in vitro fertilization. Although rapid advances in genome editing are expected to make germline gene correction feasible in a clinical setting, there are many issues that still need to be addressed before this could occur. We herein examine current status of genome editing in mammalian embryonic stem cells and zygotes and discuss potential issues in the international regulatory landscape regarding human germline gene modification. Moreover, we address some ethical and social issues that would be raised when each country considers whether genome editing-mediated germline gene correction for preventive medicine should be permitted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1477-7827-12-108

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Engineered nuclease-induced genome editing pathways. Double-stranded breaks (DSBs) are induced at a targeted sequence by a microorganism-originated, engineered nuclease. Non-homologous end-joining (NHEJ) is a DSB repair pathway that ligates or joins two broken ends together, resulting in the introduction of small insertions or deletions (indels) at the site of the DSB. Homology-directed repair (HDR) is a DNA template-dependent pathway for DSB repair, using a homology-containing donor template along with a site-specific nuclease, enabling the insertion of single or multiple transgenes (gene addition) in addition to single-nucleotide substitutions in which an amino acid substitution of a protein occurs (gene modification), or a mutation is completely repaired in the resultant organism genome (gene correction).
Figure 1 Engineered nuclease-induced genome editing pathways. Double-stranded breaks (DSBs) are induced at a targeted sequence by a microorganism-originated, engineered nuclease. Non-homologous end-joining (NHEJ) is a DSB repair pathway that ligates or joins two broken ends together, resulting in the introduction of small insertions or deletions (indels) at the site of the DSB. Homology-directed repair (HDR) is a DNA template-dependent pathway for DSB repair, using a homology-containing donor template along with a site-specific nuclease, enabling the insertion of single or multiple transgenes (gene addition) in addition to single-nucleotide substitutions in which an amino acid substitution of a protein occurs (gene modification), or a mutation is completely repaired in the resultant organism genome (gene correction).CC BY · PubMed Central
Figure 2 Embryonic stem cell approach and zygote approach for genome editing-mediated gene correction to prevent a genetic disease. Zygotes with a mutation are treated with genome editing-mediated gene correction via embryonic stem cell approach or zygote approach. After embryo screening by preimplantation genetic diagnosis, one or more embryos which have a corrected gene with no off-target mutations are subjected to embryo transfer. NIPT can be used to confirm the genetic condition of the fetus. Subsequently, CVS or amniocentesis can confirm whether a fetus has genetic mosaic mutations. Long-term follow-up is required even after a successful birth owing to the contribution of the modified germline to the entire body. CVS: chorionic villus sampling, ESCs: embryonic stem cells, ET: embryo transfer, ICSI: intracytoplasmic sperm injection, IVF: in vitro fertilization, NIPT: non-invasive prenatal genetic testing, NT: nuclear transfer.
Figure 2 Embryonic stem cell approach and zygote approach for genome editing-mediated gene correction to prevent a genetic disease. Zygotes with a mutation are treated with genome editing-mediated gene correction via embryonic stem cell approach or zygote approach. After embryo screening by preimplantation genetic diagnosis, one or more embryos which have a corrected gene with no off-target mutations are subjected to embryo transfer. NIPT can be used to confirm the genetic condition of the fetus. Subsequently, CVS or amniocentesis can confirm whether a fetus has genetic mosaic mutations. Long-term follow-up is required even after a successful birth owing to the contribution of the modified germline to the entire body. CVS: chorionic villus sampling, ESCs: embryonic stem cells, ET: embryo transfer, ICSI: intracytoplasmic sperm injection, IVF: in vitro fertilization, NIPT: non-invasive prenatal genetic testing, NT: nuclear transfer.CC BY · PubMed Central
Figure 3 An international regulatory landscape regarding human germline gene modification. Thirty nine countries were surveyed and categorized as “Ban based on legislation” (25, pink), “Ban based on guidelines” (4, faint pink), “Ambiguous” (9, gray), and “Restrictive” (1, light gray). Non-colored countries were excluded in this survey. See also Additional file 1: Table S1.
Figure 3 An international regulatory landscape regarding human germline gene modification. Thirty nine countries were surveyed and categorized as “Ban based on legislation” (25, pink), “Ban based on guidelines” (4, faint pink), “Ambiguous” (9, gray), and “Restrictive” (1, light gray). Non-colored countries were excluded in this survey. See also Additional file 1: Table S1.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 82 references

Research works printed but not linked: 1

  1. Lokody I: Genetic therapies: Correcting genetic defects with CRISPRCas9. Nat Rev Genet 2013, 15:63-63.

Cited by

See all 150

Metadata

Authors
Araki, M., & Ishii, T.
Affiliations
Hokkaido University (JP)
Corresponding author
Ishii, Tetsuya
Venue
Reproductive Biology and Endocrinology
Published
2014
Volume
12
Issue
1
Pages
108
ISSN
1477-7827 (ISSN-L)
OpenAlex
W2160704433
Cited by
150
References
82
Citations by year
2026: 3 · 2025: 11 · 2024: 2 · 2023: 7 · 2022: 16 · 2021: 13 · 2020: 23 · 2019: 22 · 2018: 17 · 2017: 15 · 2016: 13 · 2015: 8
FWCI
1.13
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Reproductive Biology and Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by)
  • Hokkaido University Collection of Scholarly and Academic Papers (Hokkaido University) (submittedVersion, cc-by)
Funders
Japan Society for the Promotion of Science (26460586)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Animal Genetics and Reproduction
Keywords
genome editing, in vitro fertilization, assisted reproduction, CRISPR-Cas, zinc finger nucleases, TALEN, zygote, genetic disease prevention, social problems
MeSH terms
Animals, Fertilization in Vitro, Genetic Engineering, Health Policy, Humans, Global Health, Genome, Human, Genomics, Genetic Diseases, Inborn, Targeted Gene Repair, Translational Research, Biomedical, Stem Cell Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: International regulatory landscape and integration of corrective genome editing into in vitro fertilization. https://app.cochat.ai/papers/10.1186/1477-7827-12-108
The paper
Araki, M., & Ishii, T. (2014). International regulatory landscape and integration of corrective genome editing into in vitro fertilization. Reproductive Biology and Endocrinology. https://doi.org/10.1186/1477-7827-12-108

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.